Dysregulated expression of SKP2 and its role in hematological malignancies. Issue 5 (4th May 2018)

• Record Type: Journal Article
• Authors: Kulinski, Michal; Achkar, Iman W.; Haris, Mohammad; Dermime, Said; Mohammad, Ramzi M.; Uddin, Shahab
• Is Part Of: Leukemia & lymphoma. Volume 59:Issue 5(2018)
• Page Start: 1051
• Page End: 1063
• Publication Date: 2018-05-04
• Subjects: Proteasome pathways -- SKP2 -- proto-oncogene -- p27Kip1 -- hematological malignancies; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2017.1359740
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: S-phase kinase-associated protein 2 (SKP2) is a well-studied F-box protein and a critical part of the Skp1-Cul1-Fbox (SCF) E3 ligase complex. It controls cell cycle by regulating the expression level of p27 and p21 through ubiquitination and proteasomal degradation. SKP2-mediated loss of p27Kip1 is associated with poor clinical outcome in various types of cancers including hematological malignancies. It is however well established that SKP2 is an oncogene, and its targeting may be an attractive therapeutic strategy for the management of hematological malignancies. In this article, we have highlighted the recent findings from our group and other investigators regarding the role of SKP2 in the pathogenesis of hematological malignancies.